Family · cognitive
Semax
MEHFPGP; ACTH(4-10) heptapeptide analog; Semax-Amur (brand, Russia)
Semax is a synthetic heptapeptide derived from an inactive fragment of adrenocorticotropic hormone, ACTH(4-10), modified with a Pro-Gly-Pro tripeptide extension for metabolic stability. It has negligible hormonal (corticotropic) activity; instead, animal and in vitro work indicates it interacts with melanocortin receptors and upregulates expression of brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) in the hippocampus and cortex, alongside effects on dopaminergic and serotonergic signaling described in rodent studies.
Evidence is dominated by decades of Russian-language research and small, mostly non-randomized or open-label Russian clinical studies, plus a substantial body of rodent/animal pharmacology; it has not been evaluated in large randomized trials published in leading Western journals. A cited non-randomized clinical study in ischemic stroke patients (n=110) reported that intranasal Semax raised plasma BDNF and was associated with better Barthel Index and motor-scale recovery compared with a non-Semax comparator group, in both early- and late-rehabilitation subgroups. Separate rodent studies show Semax and its Pro-Gly-Pro metabolite activate neurotrophin and neurotrophin-receptor gene transcription after experimental cerebral ischemia. Given the study designs (small samples, open-label or non-randomized in the clinical work), findings should be read as preliminary/mechanistic rather than confirmatory.
- Clinical use in Russia/CIS for post-stroke and cerebrovascular rehabilitation, under prescription
- Research interest in neurotrophin (BDNF/NGF) modulation and cognitive/attention performance outside that regulatory context
Educational overview only — no dosing instructions in the public hub.
Russian clinical literature reports it as generally well tolerated with few adverse events in the populations studied, but rigorous, large-scale, placebo-controlled safety data (as required by Western regulators) are lacking. As an unapproved, unregulated substance in the EU/US/UK, material quality, dosing accuracy, and sterility cannot be assumed, and there is no independent long-term human pharmacovigilance outside Russia/CIS.
Any Semax obtained outside a Russian pharmacy/prescription channel should be treated as Research Use Only. Independent third-party CoA (identity + purity by HPLC, quantification, and mass-spec confirmation) is the minimum bar; the peptide's short chain and susceptibility to degradation make lot-specific verification particularly important.
Russia/CIS: approved prescription medicine, listed on Russia's List of Vital & Essential Drugs, used clinically for stroke recovery and related indications since the 1990s. EU/UK/US: not approved by the EMA, MHRA, or FDA as a medicinal product; it has no recognized therapeutic indication in these jurisdictions and is sold there, when available, only as an unapproved research chemical (RUO), outside any medical or regulatory oversight.
Frequently asked questions
- What is Semax used for?
- Clinical use in Russia/CIS for post-stroke and cerebrovascular rehabilitation, under prescription. Research interest in neurotrophin (BDNF/NGF) modulation and cognitive/attention performance outside that regulatory context. Evidence is dominated by decades of Russian-language research and small, mostly non-randomized or open-label Russian clinical studies, plus a substantial body of rodent/animal pharmacology; it has not been evaluated in large randomized trials published in leading Western journals. A cited non-randomized clinical study in ischemic stroke patients (n=110) reported that intranasal Semax raised plasma BDNF and was associated with better Barthel Index and motor-scale recovery compared with a non-Semax comparator group, in both early- and late-rehabilitation subgroups. Separate rodent studies show Semax and its Pro-Gly-Pro metabolite activate neurotrophin and neurotrophin-receptor gene transcription after experimental cerebral ischemia. Given the study designs (small samples, open-label or non-randomized in the clinical work), findings should be read as preliminary/mechanistic rather than confirmatory.
- Is Semax legal in Europe?
- Russia/CIS: approved prescription medicine, listed on Russia's List of Vital & Essential Drugs, used clinically for stroke recovery and related indications since the 1990s. EU/UK/US: not approved by the EMA, MHRA, or FDA as a medicinal product; it has no recognized therapeutic indication in these jurisdictions and is sold there, when available, only as an unapproved research chemical (RUO), outside any medical or regulatory oversight.
- What are the risks and side effects of Semax?
- Russian clinical literature reports it as generally well tolerated with few adverse events in the populations studied, but rigorous, large-scale, placebo-controlled safety data (as required by Western regulators) are lacking. As an unapproved, unregulated substance in the EU/US/UK, material quality, dosing accuracy, and sterility cannot be assumed, and there is no independent long-term human pharmacovigilance outside Russia/CIS.
- How is the quality of Semax assessed?
- Any Semax obtained outside a Russian pharmacy/prescription channel should be treated as Research Use Only. Independent third-party CoA (identity + purity by HPLC, quantification, and mass-spec confirmation) is the minimum bar; the peptide's short chain and susceptibility to degradation make lot-specific verification particularly important.